
MMED Stock Forecast & Price Target
MMED Analyst Ratings
Bulls say
Minimed Group is expected to experience sustained growth and profits due to its strong product pipeline, direct-to-consumer sales, and potential in both developed and developing markets. Despite competitive pressures and regulatory challenges, the company has a successful track record and a customer-focused approach. With a neutral rating and positive price target from BTIG, MiniMed is a promising investment in the medical technology industry.
Bears say
Minimed Group is facing significant competition in the diabetes management market with many players focused on developing innovative products. Additionally, the uncertainty surrounding Medicare's competitive bidding program in 2028 could impact the company's revenue growth. Despite its strong international presence and leadership in multiple markets, about 60% of its revenue comes from just 10 countries, leaving it vulnerable to economic and regulatory changes in those regions. While the company has a strong portfolio of products and is investing in next-generation technologies, it faces challenges in expanding its market share in the highly competitive diabetes management industry.
This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.
MMED Analyst Forecast & Price Prediction
Start investing in MMED
Order type
Buy in
Order amount
Est. shares
0 shares